Final Day to Acquire Concord Biotech Shares for Bonus Issue
Investors have until the end of today to purchase shares of Concord Biotech to qualify for a 1:1 bonus share issuance.
Concord Biotech's record date for bonus shares is November 4.
Investors must buy shares before the record date to be eligible.
The company will issue 10.46 crore bonus shares at a face value of Re 1.
Concord Biotech has announced that today is the last opportunity for investors to buy shares in order to qualify for a 1:1 bonus share issuance. The record date for this corporate action is set for November 4, meaning that only those who hold shares in their demat accounts by this date will receive the bonus shares.
The company, which has been associated with the late investor Rakesh Jhunjhunwala, revealed the bonus issue in September, approving the distribution of 10.46 crore shares from its share premium account. The bonus shares will be allotted to eligible shareholders by November 5. To ensure eligibility, investors must purchase shares at least one trading day prior to the record date, adhering to the Securities and Exchange Board of India’s T+1 settlement cycle.
A bonus issue is generally viewed as a positive indicator of a company’s financial health, as it reflects confidence in growth prospects. While the issuance increases the total number of shares, it does not alter the company’s market capitalization. The 1:1 ratio means shareholders will receive one additional share for each share they own as of the record date, potentially enhancing liquidity and making the stock more accessible to a broader range of investors.
Rakesh Jhunjhunwala, known as India's Warren Buffett, made significant investments in Concord Biotech, first in 2004 and later during its IPO in 2023. His firm, RARE Enterprises, held a substantial stake in the company, which has seen fluctuations in its stock price, dropping over 11% in the past week alone. As of the end of September 2026, Jhunjhunwala and his associates held about 24% of Concord Biotech.
Looking ahead, investors are encouraged to act quickly if they wish to benefit from the bonus issue. The company’s shares have experienced a decline of nearly 13% this year, and the market capitalization stands at approximately Rs 12,172 crore. The upcoming days will be crucial for shareholders as they await the allocation of bonus shares and assess the stock's performance in the market.
